Health GSK expects pivotal GIST data in 2027 as Japan grants velzatinib orphan status By Ian Lyall 07:35
Health AstraZeneca lands four regulatory wins in blood pressure, bladder cancer and rare disease By Ian Lyall 3d
Health AstraZeneca shares rise 3% as Jefferies says record margin bodes well for 2027 By Ian Lyall 30/10
Health AstraZeneca reconfirms 2026 guidance as revenue rises 7% and core earnings jump 17% By Ian Lyall 30/10
Health Haleon shares plunge 12% as sales miss forces forecast cut and analysts warn of a margin reset By Ian Lyall 29/10
Health Drugs giant GSK has slipped despite beating forecasts, with investors focused on falling vaccine sales and a guarded profit outlook By Ian Lyall 28/10
Health GSK holds 2026 guidance as specialty medicines lift sales, but restructuring charge hits profit By Ian Lyall 28/10
Health JP Morgan says AstraZeneca offers compelling risk and reward ahead of rich 2027 newsflow By Ian Lyall 27/10
Health Hutchmed lung cancer combination cuts risk of death by 32% in phase III trial By Ian Lyall 26/10
Health GSK rectal cancer drug clears tumours in 76% of patients without surgery or chemotherapy By Ian Lyall 26/10
Health Jefferies keeps 'buy' on Oxford BioMedica with 57% upside after management briefing By Ian Lyall 23/10
Health GSK wins US approval for hepatitis B drug with potential to achieve functional cure By Ian Lyall 21/10